University of Campinas, Brazil
unicamp.brTotal trials
165
Active
10
Phase 3
17
Total enrollment
17,743
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dapagliflozin 10 mg | — | — | — | — | 2 | ||
| Insulin | — | — | — | — | — | 1 |
Next readouts
- 2025-10-01
- 2026-01-30
Top conditions
- Diabetes Mellitus, Type 210
- Obesity9
- Dental Caries8
- Insulin Resistance7
- Hypertension6
- Coronary Artery Disease4
- Periodontal Diseases4
- Endophthalmitis3
Frequently asked questions about University of Campinas, Brazil
- How many clinical trials does University of Campinas, Brazil have on ClinicalTrials.gov?
- University of Campinas, Brazil is listed as the lead sponsor on 165 clinical trials in ClinicalTrials.gov, 10 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Campinas, Brazil's trials are in Phase 3?
- 17 of University of Campinas, Brazil's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Campinas, Brazil focus on?
- University of Campinas, Brazil's most-studied conditions on ClinicalTrials.gov are Diabetes Mellitus, Type 2, Obesity, Dental Caries, Insulin Resistance, Hypertension.
- When are University of Campinas, Brazil's next clinical trial readouts?
- University of Campinas, Brazil has 2 upcoming primary-completion readouts tracked here; the soonest is “Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus”, expected around 2025-10-01.